Renal Cell Carcinoma
Renal Cell Carcinoma
Advertisement
Jordana JampelAdvanced Renal Cell Carcinoma | September 10, 2024
PFS was improved with nivolumab plus cabozantinib.
Read More
Karine Tawagi, MDProstate Cancer | September 10, 2024
The Two Onc Docs provide a brief overview of the the urothelial carcinoma, RCC, and prostate cancer presentations of note
Samantha Armstrong, MDProstate Cancer | September 9, 2024
Dr. Armstrong previews updates related to STAMPEDE, ARANOTE, LITESPARK-005, AMBASSADOR, and others.
Katy MarshallAdvanced Renal Cell Carcinoma | September 6, 2024
A lack of research persists on the duration of therapy as well as the safety and efficacy of reinduction at progression.
Katy MarshallAdvanced Renal Cell Carcinoma | August 28, 2024
The hypoxia-inducible factor 2α inhibitor, belzutifan, has shown clinical activity in patients with ccRCC.
Katy Beckermann, MD, PhDAdvanced Renal Cell Carcinoma | September 4, 2024
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
Katy MarshallnccRCC | August 15, 2024
Patients either underwent 54 weeks of treatment with everolimus 10 mg per day or treatment with a matching placebo.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | August 12, 2024
Dr. Braun shares insights on updates to the NCCN guidelines for RCC, highlighting how they could impact clinical practice.
Brandon TwyfordAUC3 | August 8, 2024
AUC3 seeks to reshape the landscape of GU cancer management through interdisciplinary dialogue and consensus building.
Katy MarshallAdvanced Renal Cell Carcinoma | August 5, 2024
Patients who received nivolumab plus ipilimumab experienced increased complete response rates compared with sunitinib.
Katy MarshallAdvanced Renal Cell Carcinoma | July 31, 2024
Researchers stated that the novel data source has the potential to inform patient care.
Brian Rini, MD, FASCOUromigos Live 2024 | August 2, 2024
Dr. Rini talks about the exciting sessions and entertainment in store for guests at The Uromigos Live and Unplugged 2024.
Laurence Albiges, MD, PhDnccRCC | July 29, 2024
The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC.
Laurence Albiges, MD, PhDnccRCC | July 29, 2024
The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens.
Katy MarshallProstate Cancer | July 26, 2024
Researchers focused on the economic impact of disparities related to insurance coverage.
Laurence Albiges, MD, PhDnccRCC | July 29, 2024
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
Jeffrey Rathmell, PhDRenal Cell Carcinoma Diagnostics | July 26, 2024
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. 
Jeffrey Rathmell, PhDRenal Cell Carcinoma Diagnostics | July 26, 2024
Drs. Beckermann, Rathmell, and Bacigalupa highlight the potential of ACSS2 as a therapeutic target in kidney cancer.
Emily MenendeznccRCC | July 25, 2024
CEUS for the assessment of nccRCC can provide a more sensitive alternative to conventional ultrasound imaging.
Katy MarshallAdvanced Renal Cell Carcinoma | July 23, 2024
The primary end point was ORR according to Immune Response Evaluation Criteria in Solid Tumors at 4 months.
Advertisement
Advertisement
Advertisement